Promentis Pharmaceuticals, Inc. https://validator.w3.org/feed/docs/rss2.html Founders Home Contact Scientific Advisory Board & Founders Board of Directors Promentis Pharmaceuticals Announces Positive Results for Phase 2A Study of SXC-2023 Targeting Novel Glutamatergic Mechanism and Completion of Enrollment for Phase 2 Trichotillomania Study Management Promentis Pharmaceuticals to present at the 57th annual American College of Neuropsychopharmacology (ACNP) meeting Promentis Pharmaceuticals, Inc. Announces $26M Series C Financing and Elects Four New Board Members Publications, Presentations & Events Promentis Pharmaceuticals Announces Commencement of Phase 2 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism Promentis Pharmaceuticals to present at the Society for Neuroscience conference Promentis Pharmaceuticals Commences Phase 1 Study for SXC-2023 Targeting Neuropsychiatric Disorders Press Releases Investors Promentis Pharmaceuticals to Present at the 11th Anniversary CNS Summit TRICHOTILLOMANIA SXC-2023 Technology About Promentis Promentis Pharmaceuticals to Present at the 10th Anniversary CNS Summit Promentis Pharmaceuticals Announces Successful Completion of Phase 1 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism Page Not Found! Page Not Found! Page Not Found! Michael J. Fox Foundation awards $299,000 to Promentis Pharmaceuticals, Inc. to develop Parkinson’s disease drugs In the News Searching for a cure for the brain’s darkest diseases Events Sen. Baldwin sees her first bill complementing state venture capital bill Promentis Pharmaceuticals raises $2.9 million in venture capital Promentis Pharmaceuticals Raises Nearly $3 Million in Series B Financing Promentis raises nearly $2M for schizophrenia drug development Promentis Pharmaceuticals receives funding from Michael J. Fox Foundation Promentis Pharmaceuticals, Inc. Awarded $1,800,000 Phase II SBIR Grant to Develop More Effective Drugs for the Treatment of Schizophrenia Promentis receives grant to develop schizophrenia drugs Promentis Pharmaceuticals completes venture financing Promentis Pharmaceuticals raises $2.9M Promentis raises nearly $3 million Promentis Turns to Montana Researchers to Boost Neuro Drug Tech Marquette’s New Seed Fund Underscores Entrepreneurship Push Mind Matters